Steven Snatic, MD
Neurology · Lafayette, LANPI 1184670127
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 779 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations.
Across 779 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biogen$1K
- Teva Pharmaceuticals USA, Inc.$1K
- UCB, Inc.$1K
- Amgen$956
- EMD Serono, Inc.$732
- plus $7K from 39 others
What the payments were for
- Food & beverage$15,18799%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$130
- Mavenclad$117
- AUBAGIO$108
- ZEPOSIA$103
How this compares
$15,285 in reported general payments places this provider in the 80th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 20 | $187,752 |
| VumerityDiroximel Fumarate | 18 | $164,265 |
| Avonex (4 Pack)Interferon Beta-1a | 19 | $156,258 |
| ZeposiaOzanimod Hydrochloride | 14 | $125,821 |
| Nurtec OdtRimegepant Sulfate | 37 | $74,301 |
| Glatiramer Acetate | 13 | $52,088 |
| Emgality PenGalcanezumab-Gnlm | 63 | $50,014 |
| UbrelvyUbrogepant | 32 | $45,249 |
| QuliptaAtogepant | 23 | $24,461 |
| Aimovig AutoinjectorErenumab-Aooe | 29 | $23,130 |
| VimpatLacosamide | 13 | $22,523 |
| XcopriCenobamate | 12 | $21,355 |
| AptiomEslicarbazepine Acetate | 13 | $18,836 |
| LamictalLamotrigine | 23 | $15,559 |
| Tegretol XrCarbamazepine | 14 | $14,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity, Avonex (4 Pack) | $1,395 | $508,27557 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $313 | $125,82114 claims |
| PfizerNurtec Odt | $212 | $74,30137 claims |
| AbbVieUbrelvy, Qulipta | $3,443 | $69,70955 claims |
| UCB, Inc.Vimpat | $1,052 | $22,52313 claims |
| SK Life Science, Inc.Xcopri | $224 | $21,35512 claims |
| Upsher-smith Laboratories LLCTopiramate | $12 | $58762 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 neurology providers in Louisiana.
Other neurology in Lafayette
- Fabian LugoLafayette$27K
- Kevin HargraveLafayette$21K
- Virginia KellnerLafayette$18K
- Sahil ThankiLafayette$18K
- Thomas PrivettLafayette$15K
- Adam ForemanLafayette$12K
- Jonathan JonesLafayette$12K
- Wael AlabdulkarimLafayette$11K
- Tiffany LiuLafayette$10K
- Meghan HarrisShreveport$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.